Canada approves GW Pharma’s cannabis-based drug, “Sativex”

Stuart SchlossmanAlternative therapies and devices for Multiple Sclerosis (MS), Multiple Sclerosis

By Rachel Cooper – Telegraph.co-UK
Published: 5:36PM BST 31 Aug 2010
A marijuana plant is shown at Oaksterdam University, a trade school for the cannabis industry, in Oakland, California

For a decade, GW has been developing Sativex ? a medicine derived from chemicals in cannabis, which have been shown to ease the muscle stiffness associated with multiple sclerosisPhoto: Reuters

Sativex, which is used to relieve muscle stiffness in MS patients, has been given the green light by health authorities in Canada several months earlier than expected.


The country had approved Sativex for use in neuropathic pain in 2005 – which marked the first time a cannabis-derived medicine won regulatory clearance – but authorities have now approved the drug for use in MS too.

The approval follows clearance in the UK in June and in Spain in July.

Getting the go-ahead in the UK marked a major step forward for Aim-listed GW, which had spent more than a decade developing the drug.

*

*

***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
 Multiple Sclerosis when registered at
(This will take 20-25 seconds and will empower you
 with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews